ACAD
Price
$22.12
Change
-$0.09 (-0.41%)
Updated
Jun 27 closing price
Capitalization
3.7B
31 days until earnings call
HRTX
Price
$2.14
Change
-$0.02 (-0.93%)
Updated
Jun 27 closing price
Capitalization
326.49M
44 days until earnings call
Interact to see
Advertisement

ACAD vs HRTX

Header iconACAD vs HRTX Comparison
Open Charts ACAD vs HRTXBanner chart's image
ACADIA Pharmaceuticals
Price$22.12
Change-$0.09 (-0.41%)
Volume$3M
Capitalization3.7B
Heron Therapeutics
Price$2.14
Change-$0.02 (-0.93%)
Volume$5.48M
Capitalization326.49M
ACAD vs HRTX Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. HRTX commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and HRTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ACAD: $22.12 vs. HRTX: $2.14)
Brand notoriety: ACAD and HRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 134% vs. HRTX: 326%
Market capitalization -- ACAD: $3.7B vs. HRTX: $326.49M
ACAD [@Biotechnology] is valued at $3.7B. HRTX’s [@Biotechnology] market capitalization is $326.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileHRTX’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • HRTX’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than HRTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while HRTX’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • HRTX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, HRTX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -2.60% price change this week, while HRTX (@Biotechnology) price change was +7.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

HRTX is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.7B) has a higher market cap than HRTX($326M). HRTX YTD gains are higher at: 39.869 vs. ACAD (20.545). ACAD has higher annual earnings (EBITDA): 102M vs. HRTX (2.76M). ACAD has more cash in the bank: 682M vs. HRTX (50.7M). ACAD has less debt than HRTX: ACAD (56M) vs HRTX (177M). ACAD has higher revenues than HRTX: ACAD (996M) vs HRTX (149M).
ACADHRTXACAD / HRTX
Capitalization3.7B326M1,136%
EBITDA102M2.76M3,698%
Gain YTD20.54539.86952%
P/E Ratio16.15N/A-
Revenue996M149M668%
Total Cash682M50.7M1,345%
Total Debt56M177M32%
FUNDAMENTALS RATINGS
ACAD vs HRTX: Fundamental Ratings
ACAD
HRTX
OUTLOOK RATING
1..100
5519
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
26100
PRICE GROWTH RATING
1..100
4248
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as HRTX (67). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for HRTX (100). This means that ACAD’s stock grew significantly faster than HRTX’s over the last 12 months.

ACAD's Price Growth Rating (42) in the Biotechnology industry is in the same range as HRTX (48). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

ACAD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as HRTX (100). This means that ACAD’s stock grew similarly to HRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADHRTX
RSI
ODDS (%)
Bearish Trend 3 days ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
66%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
87%
MACD
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
70%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 12 days ago
73%
N/A
Declines
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EGFEF3.27N/A
N/A
EUROBANK ERGASIAS SVCS AND HOLDINGS SA
HUBV0.11N/A
N/A
Hubb Ventures Inc.
JNPKF22.25N/A
N/A
Jenoptik AG
HONT117.35N/A
N/A
Honat Bancorp, Inc.
DSNKY22.88-0.08
-0.35%
Daiichi Sankyo Co., Ltd.

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with INZY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then INZY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-0.41%
INZY - ACAD
50%
Loosely correlated
-0.25%
AURA - ACAD
45%
Loosely correlated
-0.16%
CRSP - ACAD
43%
Loosely correlated
N/A
PGEN - ACAD
40%
Loosely correlated
-0.70%
PRME - ACAD
40%
Loosely correlated
-8.68%
More

HRTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with ABOS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HRTX
1D Price
Change %
HRTX100%
-0.93%
ABOS - HRTX
39%
Loosely correlated
-7.44%
ACAD - HRTX
39%
Loosely correlated
-0.41%
ARDX - HRTX
38%
Loosely correlated
+0.14%
ABSI - HRTX
37%
Loosely correlated
-3.32%
RNAC - HRTX
36%
Loosely correlated
-6.81%
More